DNA
AKT1 | ARID1A | BRCA1 | PIK3CA | CCNE1 | CTNNB1 | ERBB2 | RB1 | FBXW7 | FGFR2 |
KRAS | MYC | BRCA2 | PIK3R1 | POLE | PPP2R1A | ERBB3 | PTEN | TP53 |
FUSION
NTRK1 Fusion | NTRK2 Fusion | NTRK3 Fusion | RET Fusion | PD-L1 IHC | Microsatellite Instability (MSI) |
Method: Next Generation Sequencing (NGS)
Sample Type: Tissue, Blood (Liquid Biopsy Tube)
Result Time: 20-25 Days
Sensitivity: 99%
Description: 12 Gen - 4 Fusion + MSI + PD-L1 IHC
OVER PLUS PANEL
✓ Paraffin Block ✓ Liquid Biopsy
OVER PLUS PANEL
Postoperative chemotherapy is still the cornerstone of treatment for ovarian cancer. The possibility of disease recurrence after chemotherapy is quite high. Recently, PARP Inhibitors, one of the smart pill therapies, are used as maintenance after chemotherapy in patients with BRCA mutation, reducing the risk of disease recurrence by up to 70%. Therefore, BRCA mutation analysis is strongly recommended in ovarian cancer.